{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T02:28:08Z","timestamp":1786415288023,"version":"build-2736575974"},"reference-count":28,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009009","name":"Novartis Pharmaceuticals Canada Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008794","name":"Research Manitoba","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008794","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cjcopen.ca","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CJC Open"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.cjco.2026.04.010","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T21:33:16Z","timestamp":1777930396000},"page":"1010-1018","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Prevalence, Healthcare Resource Utilization, and Clinical Characteristics of Individuals with Atherosclerotic Cardiovascular Disease in Manitoba"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7046-0358","authenticated-orcid":false,"given":"Reid","family":"Whitlock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Komenda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Bamforth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Rojas-Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Hingwala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjco.2026.04.010_bib1","first-page":"CD007957","article-title":"Low-fat diets for acquired hypercholesterolaemia","volume":"2011","author":"Smart","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cjco.2026.04.010_bib2","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-016461","article-title":"Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis","volume":"7","author":"Akioyamen","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.cjco.2026.04.010_bib3","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1001\/jama.282.21.2043","article-title":"Preventing coronary artery disease by lowering cholesterol levels: fifty years from bench to bedside","volume":"282","author":"Steinberg","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.cjco.2026.04.010_bib4","first-page":"884","article-title":"Treatment and low-density lipoprotein cholesterol management in patients diagnosed with clinical atherosclerotic cardiovascular disease in Alberta","volume":"35","author":"Chen","year":"2019","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjco.2026.04.010_bib5","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.cjco.2021.10.003","article-title":"Increasing prevalence and incidence of atherosclerotic cardiovascular disease in adult patients in Ontario, Canada from 2002 to 2018","volume":"4","author":"Mackinnon","year":"2022","journal-title":"CJC Open"},{"key":"10.1016\/j.cjco.2026.04.010_bib6","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1001\/jama.295.13.jpc60002","article-title":"Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial","volume":"295","author":"Nissen","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.cjco.2026.04.010_bib7","series-title":"Population health impact of statin treatment in Canada","author":"Hennessy","year":"2016"},{"key":"10.1016\/j.cjco.2026.04.010_bib8","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1093\/jamia\/ocx078","article-title":"Assessing the quality of administrative data for research: a framework from the Manitoba Centre for Health Policy","volume":"25","author":"Smith","year":"2018","journal-title":"J Am Med Inform Assoc"},{"key":"10.1016\/j.cjco.2026.04.010_bib9","first-page":"1129","article-title":"2021 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults","volume":"37","author":"Pearson","year":"2021","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjco.2026.04.010_bib10","series-title":"Defining and validating chronic diseases: an administrative data approach. an update with ICD-10-CA","author":"Lix","year":"2008"},{"key":"10.1016\/j.cjco.2026.04.010_bib11","series-title":"The cost of smoking: a Manitoba study","author":"Martens","year":"2015"},{"key":"10.1016\/j.cjco.2026.04.010_bib12","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1053\/j.ajkd.2019.08.028","article-title":"Peripheral artery disease: its adverse consequences with and without CKD","volume":"75","author":"Bourrier","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.cjco.2026.04.010_bib13","first-page":"1210","article-title":"Simplified Canadian definition for familial hypercholesterolemia","volume":"34","author":"Ruel","year":"2018","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjco.2026.04.010_bib14","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/pds.1230","article-title":"Methods for evaluation of medication adherence and persistence using automated databases","volume":"15","author":"Andrade","year":"2006","journal-title":"Pharmacoepidemiol Drug Safety"},{"issue":"suppl 2","key":"10.1016\/j.cjco.2026.04.010_bib15","first-page":"S46","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"Stone","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.cjco.2026.04.010_bib16","first-page":"1263","article-title":"2016 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult","volume":"32","author":"Anderson","year":"2016","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjco.2026.04.010_bib17","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ijcard.2020.09.053","article-title":"Predicting 10-year risk of recurrent cardiovascular events and cardiovascular interventions in patients with established cardiovascular disease: results from UCC-SMART and REACH","volume":"325","author":"van't Klooster","year":"2021","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cjco.2026.04.010_bib18","series-title":"Patient cost estimator: methodology notes and glossary","year":"2023"},{"key":"10.1016\/j.cjco.2026.04.010_bib19","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1002\/clc.23732","article-title":"Prevalence of atherosclerotic cardiovascular disease and subsequent major adverse cardiovascular events in Alberta, Canada: a real-world evidence study","volume":"44","author":"Chen","year":"2021","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.cjco.2026.04.010_bib20","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/clc.23935","article-title":"Nonadherence to lipid-lowering therapy and strategies to improve adherence in patients with atherosclerotic cardiovascular disease","volume":"46","author":"Desai","year":"2023","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.cjco.2026.04.010_bib21","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2147\/VHRM.S146266","article-title":"Clinical characteristics, patterns of lipid-lowering medication use, and health care resource utilization and costs among patients with atherosclerotic cardiovascular disease","volume":"14","author":"Power","year":"2018","journal-title":"Vasc Health Risk Manage"},{"key":"10.1016\/j.cjco.2026.04.010_bib22","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jacc.2014.09.088","article-title":"Underutilization of high-intensity statin therapy after hospitalization for coronary heart disease","volume":"65","author":"Rosenson","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjco.2026.04.010_bib23","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/clc.22343","article-title":"Is high-intensity statin therapy associated with lower statin adherence compared with low-to moderate-intensity statin therapy? Implications of the 2013 American College of Cardiology\/American Heart Association Cholesterol Management Guidelines","volume":"37","author":"Virani","year":"2014","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.cjco.2026.04.010_bib24","doi-asserted-by":"crossref","first-page":"526","DOI":"10.7326\/0003-4819-158-7-201304020-00004","article-title":"Discontinuation of statins in routine care settings: a cohort study","volume":"158","author":"Zhang","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cjco.2026.04.010_bib25","doi-asserted-by":"crossref","first-page":"e389","DOI":"10.1161\/CIRCULATIONAHA.114.013189","article-title":"Statin intolerance","volume":"131","author":"Fitchett","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.cjco.2026.04.010_bib26","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00392-016-1069-7","article-title":"Evidence-based goals in LDL-C reduction","volume":"106","author":"Soran","year":"2017","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.cjco.2026.04.010_bib27","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials","volume":"376","author":"Trialists","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.cjco.2026.04.010_bib28","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med"}],"container-title":["CJC Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589790X26001617?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589790X26001617?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T01:34:57Z","timestamp":1786412097000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589790X26001617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2589790X26001617"],"URL":"https:\/\/doi.org\/10.1016\/j.cjco.2026.04.010","relation":{},"ISSN":["2589-790X"],"issn-type":[{"value":"2589-790X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Prevalence, Healthcare Resource Utilization, and Clinical Characteristics of Individuals with Atherosclerotic Cardiovascular Disease in Manitoba","name":"articletitle","label":"Article Title"},{"value":"CJC Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjco.2026.04.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the Canadian Cardiovascular Society.","name":"copyright","label":"Copyright"}]}}